Toxicology and management of novel psychoactive drugs

Journal of Pharmacy Practice

Volumn 28, Issue 1, 2015, Pages 50-65

  Kersten, Brian P ^a   McLaughlin, Megan E ^a  

^a Buffalo General Medical Center   (United States)

Author keywords

cathinone; drug abuse; piperazine; synthetic cannabinoid; toxicity

Indexed keywords

CANNABINOID; CATHINONE; DESIGNER DRUG; ILLICIT DRUG; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; ALKALOID; PIPERAZINE; STREET DRUG;

ADVERSE OUTCOME; ANXIETY DISORDER; ARTICLE; AUDITORY HALLUCINATION; AWARENESS; CARDIOVASCULAR EFFECT; CLINICAL PHARMACOLOGY; COGNITIVE DEFECT; CONFUSION; CONTINUING EDUCATION; DELUSION; DEPRESSION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG IDENTIFICATION; DRUG INTOXICATION; DRUG METABOLISM; DYSPHORIA; EMERGENCY TREATMENT; HAZARD ASSESSMENT; HEALTH CARE PERSONNEL; HUMAN; LAW ENFORCEMENT; LEGAL ASPECT; MANAGED CARE; MEDICAL CARE; MEDICAL PERSONNEL; PARANOIA; PATIENT CARE; PHARMACODYNAMICS; PSYCHIATRIC TREATMENT; PSYCHOSIS; SUICIDAL IDEATION; TOXICITY TESTING; TOXICOLOGY; CHEMISTRY; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS;

ALKALOIDS; CANNABINOIDS; DESIGNER DRUGS; HUMANS; PIPERAZINES; PSYCHOTROPIC DRUGS; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 84924914120     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014544814     Document Type: Article

References (154)

1. Hu X, Primack BA, Barnett TE, et al. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy. 2011 ; 6: 16
2. Emergency department visits after use of a drug sold as "bath salts" - Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep. 2011 ; 60 (19). 624-625
3. Synthetic Marijuana Data: October 31, 2013. American Association of Poison Control Centers. http://www.aapcc.org/alerts/synthetic-marijuana/. Accessed November 30, 2013.
4. The DAWN Report: Drug-Related Emergency Department Visits Involving Synthetic Cannabinoids. 2012 ;:
5. Comprehensive drug information on synthetic cannabinoids - "Spice" and "K2." Hunterdon Drug Awareness Program; 2012. http://www.hdap.org/spice.html. Accessed December 7, 2013.
6. Wells DL, Ott CA. The "new" marijuana. Ann Pharmacother. 2011 ; 45 (3). 414-417
7. Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett. 2010 ; 197 (3). 157-162
8. Vandrey R, Dunn KE, Fry JA, et al. A survey study to characterize use of spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012 ; 120 (1-3). 238-241
9. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2012 ; 44 (2). 360-366
10. Deluca P, Shifano F, Davey Z, et al Spice Report by the Psychonaut Web Mapping Research Project. London: Institute of Psychiatry, King's College London ; 2009:
11. Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I. Washington, DC: US Government Printing Office ; 2011: 11075-11078.
12. Uchiyama N, Kikura-Hanajiri R, Ogata J, et al. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int. 2010 ; 198 (1-3). 31-38
13. Piggee C. Investigating a not-so-natural high. Anal Chem. 2009 ; 81 (9). 3205-3207
14. Schifano F, Corazza O, Deluca P, et al. Psychoactive drug or mystical incense? Overview of the online available information on Spice products. Int J Cult Ment Health. 2009 ; 2: 137-144
15. Gunderson EW, Haughey HM, Ait-Daoud N, et al. Spice and K2 herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012 ; 21 (4). 320-326
16. Barratt MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2013 ; 32 (2). 141-146
17. Forrester MB, Kleinschmidt K, Schwarz E, et al. Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis. 2011 ; 30 (10). 351-358
18. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol. 2008 ; 153 (2). 199-215
19. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006 ; 46: 101-122
20. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013 ; 64: 21-47
21. Atwood BK, Huffman J, Straiker A, et al. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Br J Pharmacol. 2010 ; 160 (3). 585-593
22. Atwood BK, Lee D, Straiker A, et al. CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB1 cannabinoid receptor agonists. Eur J Pharmacol. 2011 ; 659 (2-3). 139-145
23. Fantegrossi WE, Moran JH, Radominska-Pandya A, et al. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity. Life Sci. 2014 ; 97 (1). 45-54
24. Rajasekaran M, Brents LK, Franks LN, et al. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol. 2013 ; 269 (2). 100-108
25. Auwarter V, Dresen S, Weinmann W, et al. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J Mass Spectrom. 2009 ; 44 (5). 832-837
26. Young AC, Medina G, Obafemi A, et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med. 2012 1320 ; 30 (7). e5 - e7
27. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 2011 ; 117 (2-3). 152-157
28. Berry-Caban CS, Kleinschmidt PE, Rao DS, et al. Synthetic cannabinoid and cathinone use among US soldiers. US Army Med Dep J. 2012 ;: 19-24
29. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine and codeine. Ther Drug Monit. 2006 ; 28 (3). 447-453
30. Chimalakonda KC, Seely KA, Bratton SM, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispo. 2012 ; 40 (11). 2174-2184
31. Chimalakonda KC, Bratton SM, Le VH, et al. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos. 2011 ; 39 (10). 1967-1976
32. Brents LK, Zimmerman SM, Saffell AR, et al. Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: Implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther. 2013 ; 346 (3). 350-361
33. Seely KA, Prather PL, James LP, et al. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?. Mol Interv. 2011 ; 11 (1). 36-51
34. Perspectives on drugs: synthetic cannabinoids in Europe. European Monitoring Centre for Drugs and Drug Addiction; 2013. http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids. Accessed December 21, 2013.
35. Dresen S, Ferreiros N, Putz M, et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom. 2010 ; 45 (10). 1186-1194
36. Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacol. 2013 ; 228 (4). 525-540
37. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013 ; 27 (1). 19-27
38. Notes from the field: Severe illness associated with reported use of synthetic marijuana - Colorado August-September 2013. MMWR Morb Mortal Wkly Rep. 2013 ; 62 (49). 1016-1017
39. Notes from the field: severe illness associated synthetic cannabinoid use - Brunswick, Georgia, 2013. MMWR Morb Mortal Wkly Rep. 2013 ; 62 (46). 939
40. Hoyte CO, Jacob J, Monte AA, et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012 ; 60 (4). 435-438
41. Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry. 2011 ; 168 (10). 1119
42. Castellanos D, Singh S, Thornton G, et al. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Heal. 2011 ; 49 (4). 347-349
43. Schneir AB, Baumbacher T. Convulsion associated with the use of a synthetic cannabinoid product. J Med Toxicol. 2012 ; 8 (1). 62-64
44. DonnellyMT.Health advisory: K2 synthetic marijuana use among teenagers and young adults in Missouri. Jefferson, MO: Missouri Department of Health and Senior Services; 2010. http://health.mo.gov/emergencies/ert/alertsadvisories/pdf/HAd3-5-2010.pdf. Accessed December 5, 2013.
45. Lapoint J, James LP, Moran CL, et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol. 2011 ; 49 (8). 760-764
46. Freeman MJ, Rose DZ, Myers MA, et al. Ischemic stroke after use of the synthetic marijuana "spice". Neurology. 2013 ; 81 (24). 2090-2093
47. Korya D, Kapoor A, Labiner D. Ischemic stroke in a 28-year-old woman after smoking synthetic THC. Neurology. 2013 ; 80:
48. Mir A, Obafemi A, Young A, et al. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011 ; 128 (6). 1622-1627
49. Hopkins CY, Gilchrist BL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med. 2013 ; 45 (4). 544-546
50. Simmons J, Cookman L, Kang C, et al. Three cases of "Spice" exposure. Clin Toxicol. 2011 ; 49 (5). 431-433
51. Banerji S, Deutsch CM, Bronstein AC. Spice ain't so nice. Clin Toxicol. 2010 ; 48: 632
52. Acute kidney injury associated with synthetic cannabinoid use - multiple states, 2012. MMWR Morb Mortal Wkly Rep. 2013 ; 62 (6). 93-98
53. Bhanushali GK, Jain G, Fatima H, et al. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. 2013 ; 8 (4). 1-4
54. Shanks KG, Dahn T, Terrell AR. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol. 2012 ; 36 (3). 145-152
55. Kronstrand R, Roman M, Andersson M, et al. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol. 2013 ; 37 (8). 534-541
56. Patton AL, Chimalakonda KC, Moran CL, et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci. 2013 ; 58 (6). 1676-1680
57. Thomas S, Bliss S, Malik M. Suicidal ideation and self-harm following K2 use. J Okla State Med Assoc. 2012 ; 105 (11). 430-433
58. Rominger A, Cumming P, Xiong G, et al. Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D2/3 receptor availability: A [18F]fallypride PET study. Eur Neuropsychopharmacol. 2013 ; 23 (11). 1606-1610
59. Heath TS, Burroughs Z, Thompson AJ, et al. Acute intoxication caused by a synthetic cannabinoid in two adolescents. J Pediatr Pharmacol Ther. 2012 ; 17 (2). 177-181
60. Hermanns-Clausen M, Kneisel S, Szabo B, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013 ; 108 (3). 534-544
61. Bebarta VS, Ramirez S, Varney SM. Spice: a new "legal" herbal mixture abused by young active duty military personnel. Subst Abuse. 2012 ; 33 (2). 191-194
62. Treatment of Controlled Substance Analogues. Washington, DC: US Government Printing Office ; 1986: 452.
63. Schedules of Controlled Substances: United States Code. Washington, DC: US Government Printing Office ; 522-526.
64. Controlled Substances Act [Online]. Washington, DC: US Government Printing Office; 2012 579-584. http://www.gpo.gov/fdsys/pkg/USCODE-2012-title21/pdf/USCODE-2012-title21-chap13-subchapI-partB-sec812.pdf. Accessed December 9, 2013.
65. Zawilska JB, Wojcieszak J. Designer cathinones - an emerging class of novel recreational drugs. Forensic Sci Int. 2013 ; 231 (1-3). 42-53
66. Corazza O, Demetrovics W, van den Brink W, et al. 'Legal highs' an inappropriate term for 'novel psychoactive drugs' in drug prevention and scientific debate. Int J Drug Policy. 2013 ; 24 (1). 82-83
67. Coppola M, Mondola R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food". Toxicol Lett. 2012 ; 211 (2). 144-149
68. Warrick BJ, Hill M, Hekman K, et al. A 9-state analysis of designer stimulant, "Bath Salt," hospital visits reported to Poison Control Centers. Ann Emerg Med. 2013 ; 62 (3). 244-251
69. Advisory council on the misuse of drugs. Consideration of the cathinones. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/119173/acmd-cathinodes-report-2010.pdf. Accessed January 2, 2014.
70. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012 ; 8 (1). 33-42
71. Bilinski P, Holownia P, Kapka-Skrzypczak, et al. Designer drug (DD) abuse in Poland: a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof; part 1 - cannabinoids and cathinones. Ann Agric Environ Med. 2012 ; 19 (4). 857-870
72. Karila L, Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Analysis. 2011 ; 3 (9). 552-559
73. Brenneisen R, Fisch HU, Koelbing U, et al. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol. 1990 ; 30 (6). 825-828
74. Widler P, Mathys K, Brenneisen R, et al. Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin Pharmacol Ther. 1994 ; 55 (5). 556-562
75. Capriola M. Synthetic cathinone abuse. Clin Pharmacol. 2013 ; 5: 109-115
76. Balint EE, Falkay G, Balint GA. Khat - a controversial plant. Wien Klin Wochenschr. 2009 ; 121 (19-20). 604-614
77. Fayissa AM, Kelly JP. A review of the neuropharmacological properties of khat. Prog Neuropsychopharmacol Bio Psychiatry. 2008 ; 32 (5). 1147-1166
78. James D, Adams RD, Spears R, et al. Clinical characteristics of mephedrone toxicity reported to the U.K. National poisons information service. Emerg Med J. 2011 ; 28 (8). 686-689
79. DelucaPSchifanoFDaveyZ; Psychonaut WebMapping Research Group. Mephedrone Report. London, United Kingdom: Institute of Psychiatry, King's College London; 2010. http://www.psychonautproject.eu/documents/reports/Mephedrone.pdf. Accessed December 29, 2013.
80. Rikura-Hanajiri R, Uchiyama N, Goda Y. Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg Med (Tokyo). 2011 ; 13 (3). 109-115
81. Adebamiro A, Perazella MA. Recurrent acute kidney injury following bath salts intoxication. Am J Kidney Dis. 2013 ; 59 (2). 273-275
82. Erickson T. "Bath Salt" abuse hits epidemic proportions. Emerg Phys Monthly. 2011 ;:
83. Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depend. 2011 ; 118 (1). 19-22
84. Winstock AR, Mitcheson LR, Deluca P, et al. Mephedrone: new kid for the chop?. Addiction. 2010 ; 106 (1). 154-161
85. Forrester MB. Synthetic cathinone exposures reported to Texas Poison Centers. Ann J Drug Alcohol Abuse. 2012 ; 38 (6). 609-615
86. Info Sheet: MDPV. http://crew2000.org.uk. Accessed January 2, 2014.
87. Simmler LD, Buser TA, Schramm Y, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013 ; 168 (2). 458-470
88. Kamata HT, Shima N, Zaitsu K, et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica. 2006 ; 36 (8). 709-723
89. Meyer MR, Du P, Schuster F, et al. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom. 2010 ; 45 (12). 1426-1442
90. Meyer MR, Vollmar C, Schwaninger AE, et al. New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine. J Mass Spectrom. 2012 ; 47 (2). 253-262
91. Winstock A, Mitcheson L, Ramsey J, et al. Mephedrone: use, subjective effects and health risks. Addiction. 2011 ; 106 (11). 1991-1996
92. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of "Bath Salts" containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med. 2012 ; 60 (1). 103-105
93. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. Q J Med. 2010 ; 103 (11). 875-879
94. Van Hout MC, Bingham T.. "A Costly Turn ON": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy. 2012 ; 23 (3). 188-197
95. Levine M, Levitan R, Skoinik A. Compartment syndrome after bath salts. Ann Emerg Med. 2013 ; 61 (4). 480-483
96. Durham M. Ivory wave: the nextmephedrone?. Emerg Med J. 2011 ; 28 (12). 1059-1060
97. Penders TM, Gestring R. Hallucinatory delirium following use of MDPV: "Bath Salts.". Gen Hosp Psychiatry. 2011 ; 33 (5). 525-526
98. Spiller HA, Ryan ML, Weston RG, et al. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol (Phila). 2011 ; 49 (6). 499-505
99. Mixmag's Drug Survey: The results - 2012. http://www.mixmag.net/drugssurvey. Accessed January 3, 2014.
100. McCann UD, Wong DF, Yokoi F, et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 1998 ; 18 (20). 8417-8422
101. De Bie RMA, Gladstone RM, Strafella AP, et al. Manganese-induced parkinsonism associated with methcathinone (Ephedrine) abuse. Arch Neurol. 2007 ; 64 (6). 886-889
102. Stepens A, Logina I, Liguts V, et al. A parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med. 2008 ; 358 (10). 1009-1017
103. Santosky Y, Lesyk R, Fedoryshyn L, et al. Manganic encephalopathy due to "ephedrone" abuse. Mov Disord. 2007 ; 22 (9). 1337-1343
104. Mugele J, Nanagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med. 2012 ; 60 (1). 100-102
105. Lusthof KJ, Oosting R, Maes A, et al. A case of extreme agitation and death after the use of mephedrone in the Netherlands. Forensic Sci Int. 2011 ; 206 (1-3). e93 - e95
106. Aromatario M, Bottoni E, Santoni M, et al. New "Lethal highs": a case of deadly cocktail of GHB and mephedrone. Forensic Sci Int. 2012 ; 223 (1-3). e38 - e41
107. Dickson AJ, Vorce SP, Levine B, et al. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol. 2010 ; 34 (3). 162-168
108. Maskell PD, De Paoli G, Seneviratne C, et al. Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol. 2011 ; 35 (3). 188-191
109. Imam SF, Patel H, Mahmoud M, et al. Bath salts intoxication: a case series. J Emerg Med. 2013 ; 45 (3). 361-365
110. Adamowicz P, Tokarczyk B, Stanaszek, et al. Fatal mephedrone intoxication - a case report. J Anal Toxicol. 2013 ; 37 (1). 37-42
111. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug "Bath Salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol. 2012 ; 8 (1). 69-75
112. Otachbachi M, Cevik C, Bagdure S, et al. Excited delirium, restraints, and unexpected death. Am J Forensic Med Pathol. 2010 ; 31 (2). 107-112
113. Al Habori M. The potential adverse effects of habitual use of Catha edulis (khat). Expert Opin Drug Saf. 2005 ; 4 (6). 1145-1154
114. Torrance H, Cooper G. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int. 2010 ; 202 (1-3). e62 - e63
115. Wikstrom M, Thelander G, Nystrom I, et al. Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone). J Anal Toxicol. 2010 ; 34 (9). 594-598
116. Griffiths P, Lopez D, Sedefov R, et al. Khat use and monitoring drug use in Europe: the current situation and issues for the future. J Ethnopharmacol. 2010 ; 132 (3). 578-583
117. Elliott S. Current awareness of piperazines: pharmacology and toxicology. Drug Test Anal. 2011 ; 3 (7-8). 430-438
118. Mauer HH, Kraemer T, Springer D, et al. Chemistry, pharmacology, toxicology and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidinophenone types. Ther Drug Monit. 2004 ; 26: 127-131
119. Kalant H. The pharmacology and toxicology of "Ecstasy" (MDMA) and related drugs. CMAJ. 2001 ; 165 (7). 917-928
120. Sa Monteiro M, de Lourdes Vastos M, Guedes de Pinho P, et al. Update on 1-benzylpiperazine (BZP) party pills. Arch Toxicol. 2013 ; 87 (6). 929-947
121. Gee P, Richardson S, Woltersdorf W, et al. Toxic effect of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J. 2005 ; 118 (1227). 1-10
122. Fong MH, Garattini S, Caccia S. 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole. J Pharm Pharmacol. 1982 ; 34 (10). 674-675
123. Arbo MD, Bastos ML, Carmo HF. Piperazine compounds as drugs of abuse. Drug Alcohol Depend. 2012 ; 122 (3). 174-185
124. Nicholson TC. Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department. Emerg Med Australas. 2006 ; 18 (2). 180-184
125. Wilkins C, Sweetsur P, Girling M. Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample of New Zealand. Drug Alcohol Rev. 2008 ; 27 (6). 633-639
126. Butler RA, Sheridan JL. Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand. Harm Reduct J. 2007 ; 4: 18
127. Lin JC, Bangs N, Lee H, et al. Determining the subjective and physiological effects of BZP on human females. Psychopharmacology (Berl). 2009 ; 207 (3). 439-446
128. Lin JC, Jan RK, Lee H, et al. Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology (Berl). 2011 ; 214 (3). 761-768
129. Antia U, Lee HS, Kydd RR, et al. Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci Int. 2009 ; 186 (1-3). 63-67
130. Antia U, Tingle MD, Russel BR. In vivo interactions between BZP and TFMPP (party pill drugs). N Z Med J. 2009 ; 122 (1303). 29-38
131. Gee P, Gilbert M, Richardson S, et al. Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol. 2008 ; 46 (9). 802-807
132. Bilinski P, Holownia P, Kapka-Skrzypczak, et al. Designer Drug (DD) abuse in Poland: a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof: part II - piperazines/piperidines, phenylethylamines, tryptamines and miscellaneous 'others'. Ann Agric Environm Med. 2012 ; 19 (4). 871-882
133. Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow... and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (Bath Salts), Kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol. 2012 ; 8 (1). 15-32
134. Schep LJ, Slaughter RJ, Vale JA, et al. The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol (Phila). 2011 ; 49 (3). 131-141
135. Baumann MH, Clark RD, Budzynski AG, et al. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci. 2004 ; 1025: 189-197
136. Baumann MH, Clark RD, Budzynski AG, et al. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Neuropsychopharmacology. 2005 ; 30 (3). 550-560
137. Gijsman HK, Van Gerven J, Tieleman MC, et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol. 1998 ; 18 (4). 298-295
138. Gee P, Jerram T, Bowie D. Multiorgan failure from 1-benzylpiperazine ingestion - legal high or lethal high?. Clin Toxicol (Phila). 2010 ; 48 (3). 230-233
139. Alansari M, Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N Z Med J. 2006 ; 119 (1233). 1-3
140. Theron L, Jansen K, Miles J. Benzylpiperazine-based party pills' impact on the Auckland city hospital emergency department overdose database (2002-2004) compared with ecstasy (MDMA or methylenedioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. N Z Med J. 2007 ; 120: U2416
141. Wood DM, Dargan PI, Button K, et al. Collapse, reported seizure - and an unexpected pill. Lancet. 2007 ; 369 (9571). 1490
142. Poon WT, Lai CF, Lui MC, et al. Piperazines: a new class of drug of abuse has landed in Hong Kong. Hong Kong Med J. 2010 ; 16 (1). 76-77
143. Wood DM, Button J, Lidder S, et al. Dissociative and sympathomimetic toxicity associated with recreational use of 1(-3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperazine (BZP). J Med Toxicol. 2008 ; 4 (4). 254-257
144. Vorce SP, Holler JM, Levine B, et al. Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS. J Anal Toxicol. 2008 ; 32 (6). 444-450
145. Wilkins C, Girling M, Sweetsur P. The prevalence of use, dependency and harms of legal 'party pills' containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. J Subst Abuse. 2007 ; 12: 213-224
146. Elliott S, Smith C. Investigation of the first deaths in the United Kingdom involving the detection and quantification of the piperazines BZP and 3-TFMPP. J Anal Toxicol. 2008 ; 32 (2). 172-177
147. Dickson AJ, Vorce SP, Holler JM, et al. Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples. J Anal Toxicol. 2010 ; 34 (8). 464-469
148. De Boer D, Bosman IJ, Hidvegi E, et al. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int. 2001 ; 121 (1-2). 47-56
149. Jan RK, Lin JC, Lee H, et al. Determining the subjective effects of TFMPP in human males. Psychopharmacology. 2010 ; 211 (3). 347-353
150. Austin H, Monasterio E. Acute psychosis following ingestion of 'Rapture'. Australas Psychiatry. 2004 ; 12 (4). 406-408
151. Erowid. Documenting the complex relationship between humans & psychoactives. erowid.org. Accessed October 26, 2013.
152. National Center for Biotechnology Information PubChem Compound. CID = 16078, CID = 10382701, CID = 15942731, CID = 9821569. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid. Accessed January 2, 2014.
153. National Center for Biotechnology Information PubChem Compound. CID = 10836, CID = 62258, CID = 20111961, CID = 45266826. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid. Accessed January 3, 2014.
154. National Center for Biotechnology Information PubChem Compound. CID = 1615, CID = 75994, CID = 3084246. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid. Accessed January 3, 2014.